belzutifan (Welireg): FDA status

Approved Approved Dec 14, 2023. Indication: advanced renal cell carcinoma after PD-1/PD-L1 inhibitor and VEGF-TKI. Company: Merck.

Regulatory history

• Dec 14, 2023: Approved. FDA approved belzutifan for patients with advanced renal cell carcinoma following a PD-1 or PD-L1 inhibitor and a VEGF-TKI, based on the LITESPARK-005 trial. FDA

All products in the FDA Tracker